Introduction {#s1}
============

Stroke is the second most common cause of deaths worldwide ([@B1]) as well as the leading cause of long-term disability ([@B2], [@B3]). Post-stroke insomnia (PSI) is a common symptom but often underestimated and is even ignored in the diagnosis and treatment ([@B4]). Up to 70% of the patients with acute stroke have sleep disorders including excessive daytime sleepiness, insomnia, hypersomnia, and fatigue ([@B5]). PSI affects the functional recovery of the nervous system, aggravates the existing diseases such as hypertension and diabetes, and deteriorates the quality of life ([@B6]). Accumulating evidence demonstrated that poor quality of sleep could be detrimental to the immune system ([@B7]), delay the recovery ([@B8]), increase pain sensitivity ([@B9]), lead to depression and anxiety ([@B10]), and affect the functional well-being ([@B11]). Although the consequences of PSI and the potential clinical impact are severe, the condition is not well treated.

Reportedly, alprazolam (ALP) was the most commonly used Western drug in China due to its effectiveness on generalized anxiety, panic attacks with or without agoraphobia, and depression ([@B12]). ALP is a derivative of benzodiazepine, and the mechanism underlying the activity of the drug and the side effects have been described previously ([@B13]). Notably, ALP presents excessive side effects when more than 0.5 mg was used each time ([@B14]).

Drugs for stroke from traditional Chinese medicine have been developed ([@B15], [@B16]). According to clinical and basic research in traditional Chinese medicine, these drugs were beneficial in the prevention and treatment of stroke. BC is a traditional Chinese patent medicine. It can improve sleep quality and alleviate insomnia by elevating the level of brain contents 5-HT and GABA ([@B17], [@B18]). Previous studies have shown that sleep disorders were closely related to the decreased content of 5-HT and gamma-aminobutyric acid (GABA) in the central nervous system ([@B19]). The data were monitored, which showed that this drug might cause nausea, abdominal pain, rash, and itching. Despite mild adverse reactions, BC can alleviate PSI and anxiety, resulting in the improvement of life quality ([@B20]).

In this retrospective study, we evaluated the effect of BC, ALP, and BC combined with ALP on sleep quality and stroke outcome (self-care ability) in PSI patients.

Patients and Methods {#s2}
====================

Participants {#s2_1}
------------

In the present retrospective study, we analyzed 231 patients (78 females and 153 males) who were hospitalized for stroke at the Department of Neurology in the General Hospital of Western Theater Command from January 1, 2014, to September 1, 2015. All the patients underwent identical treatment for stroke according to the guidelines of acute ischemic stroke ([@B21]). The degrees of insomnia and neurological impairment were evaluated after admission. This study has been approved by the Ethics Committee of The General Hospital of Western Theater Command. Also, we obtained the informed consent of patients and their families.

The patient selection process was applied according to the following criteria:

*Inclusion criteria:* 1) The diagnosis of stroke is based on clinical presentation, computerized tomography, and/or magnetic resonance imaging scan of the brain when the stroke occurred within 7 days prior to the admission. 2) Patients had varying degrees of insomnia \[*Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (*DSM-IV*) criteria and the three insomnia-related items of the Hamilton depression scale\] and received ALP, BC, or both during hospitalization. 3) Insomnia was present after stroke. 4) The score was at least 26 on the Mini-Mental State Exam. 5) The questionnaire was completed independently. And 6) antipsychotic medications, if administered, had been discontinued for more than 7 days.

*Exclusion criteria:* 1) Patients had a history of sleep disorders (based on the sleep disorders questionnaire designed in Hong Kong) ([@B22]). 2) Patients also presented with cardiovascular, liver, kidney, or any severe life-threatening diseases. 3) Patients had active epilepsy and unable to complete the entire treatment process. 4) Patients had language barrier and could not cooperate with the researchers. 5) Patients had typical mental diseases, such as anxiety and depression. 6) Patients had family history of mental disorders. 7) Patients had other severe diseases and could not complete the treatment and investigation. 8) Patients had restless legs syndrome, obstructive sleep apnea--hypopnea syndrome, central sleep apnea syndromes, and rapid eye movement (REM) sleep behavior disorder.

Study Design {#s3}
============

The patients were divided into three groups according to the treatment. The patients received ALP ([@B12]) (*n* = 71, 0.4 mg/day, taken 30 min before sleep at night; Qilu Pharmaceutical Group, Jinan, Shandong, China, national drug approval number: H37021277), BC ([@B20]) (*n* = 87, four capsules each time after breakfast and dinner; Yangtze River Pharmaceutical Co., Ltd, Taizhou, Jiangsu, China, national drug approval number: Z20020131), or ALP + BC (*n* = 73) for 3 weeks. Pittsburgh Sleep Quality Index (PSQI) and modified Rankin Scale (mRS) were applied to evaluate the sleep quality and the self-care ability of patients before and after treatment. Furthermore, we also objectively assessed the data of polysomnography (PSG) before and after treatment in order to evaluate the curative effect impersonally (*n* = 5 in each group).

Assessment Criteria and Questionnaires {#s4}
======================================

*Sleep quality:* PSQI is a self-reported questionnaire tool for subjectively measuring the quality of sleep for adults in the last month. It includes seven sleep-related items, such as latency, quality, duration, disturbances, efficiency, the use of sleep medications, and daytime dysfunction. Each item is assigned a score of 0--3 points so that the total score of PSQI is 0--21. A total score of 7 means good sleep, 7--11 points indicate mild, 12--16 points moderate, and 17--21 points severe sleep disorder ([@B23]).

*PSG:* PSG was performed as reported previously ([@B24]). Two nights of PSG recording were recommended; however, the first night was regarded as the "adaptation" night and removed from the analysis as it was not representative of the usual sleeping patterns ([@B25]). Briefly, PSG was performed with an eight-channel Grass electroencephalograph in one night. The recordings included brain electrical activity, eye movements, chin muscle activity, nasal and oral airflow, thoracic and abdominal respiratory movements, heart rate, and leg movements. Also, the following parameters were recorded: total recording time, total sleeping time, sleep efficiency, sleep latency, paradoxical latency, duration of non-rapid eye movement sleep (NREM) and its three stages (N1, N2, and N3), duration of rapid eye movement sleep (REM), wake time after sleep onset, and arousal time ([@B26]).

*Clinical outcomes:* The prognosis of stroke was assessed using mRS, a commonly used scale for measuring the self-care ability.

*Adverse reactions:* During the treatment, adverse effects such as headache, aggravated insomnia, blood pressure increase, hyperethism, nausea and vomiting, dizziness, palpitation, frequent urination, somnolence, and numbness were evaluated. A total of four cases presented nausea and upper abdominal discomfort in the BC group, while no adverse reactions were detected in the other two groups. Moreover, the symptoms were relieved spontaneously without any additional treatment.

Statistical Analysis {#s5}
====================

Data analysis was carried out using SPSS 21.0 software (IBM Corp, Armonk, NY, USA). Measurement data were expressed as means ± standard deviations (SDs). One-way ANOVA, Student's *t*-test, χ^2^ test, or Mann--Whitney *U* test was utilized for group comparison. When ANOVA revealed significant differences, least significant difference (LSD) or Dunnett's T3 *post hoc* tests were used to identify significant differences among three groups. *P* \< 0.05 was considered as a statistical significance.

Results {#s6}
=======

Comparison of Demographic and Clinical Characteristics Between the Three Groups {#s6_1}
-------------------------------------------------------------------------------

No significant difference was observed in the baseline characteristics of age, sex, blood glucose, triglyceride (TG), cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C), serum uric acid, and homocysteine between the three groups (*P* \> 0.05, [**Table 1**](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of the patients. (Data are expressed as *n* (%) or mean ± SD.)

                                     ALP + BC         ALP             BC               F       P
  ------------------------- -------- ---------------- --------------- ---------------- ------- -------
  Sex                       Male     48 (65.75)       49 (69.01)      56 (32.15)       0.174   0.677
                            Female   25 (34.25)       22 (30.99)      31 (41.65)               
  Age, y                             58 ± 10.05       56.13 ± 14.28   57.95 ± 11.98    0.565   0.569
  Serum glucose, mmol/L              5.8 ± 2.11       5.47 ± 1.28     5.48 ± 1.66      0.909   0.404
  TG, mmol/L                         1.72 ± 0.98      1.93 ± 1.41     1.86 ± 1.57      0.467   0.627
  TC, mmol/L                         4.53 ± 1.23      4.42 ± 1.25     4.58 ± 1.43      0.320   0.726
  HDL-C, mmol/L                      1.1 ± 0.22       1.14 ± 0.22     1.47 ± 2.16      1.849   0.160
  LDL-C, mmol/L                      2.84 ± 0.97      2.89 ± 0.88     2.75 ± 0.92      0.450   0.638
  Serum uric acid, µmol/L            305.17 ± 86.15   315.3 ± 80.42   306.98 ± 86.05   0.298   0.742
  Homocysteine, µmol/L               15.03 ± 6.7      14.24 ± 5.99    13.84 ± 6.18     0.720   0.488

ALP, alprazolam; BC, Bailemian capsule; TG, triglyceride; TC, cholesterol; HDL-C; LDL-C.

Comparison of Sleep Quality by PSQI Before and After ALP, BC, and ALP + BC Treatment {#s6_2}
------------------------------------------------------------------------------------

The data did not show any significant difference in the sleep quality (*F* ~(2,228)~ = 1.055, *P* = 0.35), sleep latency (*F* ~(2,228)~ = 0.205, *P* = 0.815), sleep duration (*F* ~(2,228)~ = 0.169, *P* = 0.845), sleep efficiency (*F* ~(2,228)~ = 0.074, *P* = 0.929), sleep disturbances (*F* ~(2,228)~ = 0.046, *P* = 0.955), daytime dysfunction (*F* ~(2,228)~ = 0.127, *P* = 0.881), sleep medication (*F* ~(2,228)~ = 0.197, *P* = 0.822), and global score (*F* ~(2,228)~ = 0.143, *P* = 0.867) ([**Figure 1**](#f1){ref-type="fig"}) at baseline. After 3 weeks of treatment, all the three treatment groups significantly improved in all of the subjective PSQI items and global score ([**Figure 1**](#f1){ref-type="fig"}, *P* \< 0.05). Notably, ALP + BC administration exerted a significantly greater effect on all the PSQI items and the global PSQI score than did the other groups, except for the sleep duration, which was greatly affected by ALP + BC or BC as compared with ALP ([**Figure 1C**](#f1){ref-type="fig"}, *P* \< 0.05).

![Effects of alprazolam and Bailemian on PSQI components. **(A)** Sleep quality, **(B)** sleep latency, **(C)** sleep duration, **(D)** sleep efficiency, **(E)** sleep disturbances, **(F)** daytime dysfunction, and **(G)** global score were measured according to the PSQI. \**P* \< 0.01, \*\**P* \< 0.05. PSQI, Pittsburgh Sleep Quality Index; ALP, alprazolam; BC, Bailemian capsule.](fpsyt-10-00411-g001){#f1}

Comparison of Sleep Quality by PSG Before and After ALP, BC, and ALP + BC Treatment {#s6_3}
-----------------------------------------------------------------------------------

Five patients in each group were selected for PSG testing. The data did not reveal any significant difference in the arousal time, sleep efficiency, sleep latency, total sleep time, wake after sleep onset, REM sleep, and NREM sleep at baseline (*P* \> 0.05). After 3 weeks of treatment, ALP improved the sleep efficiency and decreased the arousal times, sleep latency, and REM sleep ([**Figure 2A, B, C & F**](#f2){ref-type="fig"}), while BC significantly improved the sleep efficiency, total sleep time, and the duration of N3 ([**Figure 2B, D & I**](#f2){ref-type="fig"}); ALP + BC achieved the effect of both ALP and BC ([**Figure 2A, B, C, D, E & I**](#f2){ref-type="fig"}; *P* \< 0.05). There was a significant difference in sleep latency (*F* ~(2,12)~ = 28.407, *P* \< 0.001) and total sleep time (*F* ~(2,12)~ = 5.701, *P* = 0.018) among the three groups after treatment. *Post hoc* analysis indicated that ALP significantly decreased sleep latency compared to BC ([**Figure 2C**](#f2){ref-type="fig"}, *P* = 0.028), while BC significantly increased total sleep time compared to ALP ([**Figure 2D**](#f2){ref-type="fig"}, *P* = 0.026). Importantly, the effect of the combination of ALP and BC was greater than that of ALP or BC alone, which was consistent with the result of PSQI.

![Effects of alprazolam and Bailemian on the quality of sleep in patients tested by polysomnography (PSG). **(A)** Arousal times (total number across the night), **(B)** sleep efficiency, **(C)** sleep latency, **(D)** total sleep time, **(E)** wake after sleep onset, **(F)** duration of rapid eye movement, and duration of non-rapid eye movement sleep and its three stages **(G)** N1, **(H)** N2, and **(I)** N3 were measured and compared. \**P* \< 0.05, ^\#^ *P* \< 0.01. ALP, alprazolam; BC, Bailemian capsule.](fpsyt-10-00411-g002){#f2}

Comparison of Self-Care Ability Before and After ALP, BC, and ALP + BC Treatment {#s6_4}
--------------------------------------------------------------------------------

Previous studies showed that PSI could affect the recovery of neurological function in stroke patients ([@B6]). Therefore, we explored the effect of insomnia improvement on stroke outcome. After treatment, the stroke outcome was improved in all of the three groups, in which the mRS score decreased (*P* \< 0.05). The *post hoc* study demonstrated that this effect of ALP + BC was greater than that of ALP or BC alone ([**Figure 3**](#f3){ref-type="fig"}, *P* \< 0.05).

![Effects of alprazolam and Bailemian on stroke outcome assessed by the modified Rankin Scale (mRS). \**P* \< 0.001.](fpsyt-10-00411-g003){#f3}

Discussion {#s7}
==========

The present study examined the therapeutic effect of ALP, BC, and the combined effect of ALP and BC on improving the sleep quality and self-care ability in patients with PSI. The results revealed that the oral administration of ALP and BC alone significantly but differentially improves the subjective perception of sleep quality by PSQI and objective sleep quality by PSG. However, the combined effect of ALP and BC is better than that of ALP or BC alone.

Next, compared with the baseline, ALP + BC administration had a significantly greater effect on sleep latency, quality, disturbance, and efficiency than did either ALP or BC alone, which was consistent with objective PSG and subjective PSQI. In addition, in comparison with the baseline after the use of BC or ALP, PSQI data showed that all items of PSQI were improved. Surprisingly, after 3 weeks of treatment, among the 15 patients (*n* = 5 in each group), the PSG data showed that ALP improved the sleep efficiency and decreased the arousal times, sleep latency, and REM sleep, while BC improved the sleep efficiency, total sleep time, and duration of N3 significantly. This discrepancy between subjective and objective data might be attributed to the smaller sample size of PSG patients than PSQI patients as well as the minor differences in the areas of sleep improvement targeted by ALP and BC therapies.

With the improvement in insomnia, patients' self-care ability has also been enhanced effectively. A previous study demonstrated that sleep disorders could impact the daytime functioning and quality of life ([@B11]), which was confirmed by improved daytime dysfunction of PSQI after treatment. Furthermore, the self-care ability can be enhanced by improving the nervous system and immune system and alleviating the basic diseases such as hypertension and diabetes ([@B6], [@B7]). Thus, the mechanism underlying the improvement of insomnia symptoms and self-care ability after stroke needs to be explored further along with the start time and course of treatment for PSI.

BC is a traditional Chinese patent medicine, composed of 15 Chinese herbal extractions. *Acanthopanax senticosus*, one of the main components of BC, plays an anxiolytic role *via* the regulation of autonomic function and increases the signal of the hippocampus *via* brain-derived neurotrophic factor (BDNF) ([@B27]). Semen Ziziphi spinosae (*Suanzaoren* in Chinese) and Radix et Rhizoma Salviae miltiorrhizae (*Danshen* in Chinese), the other two major components of BC, are well-known conventional herbal drugs in traditional Chinese medicine and have been used widely for the treatment of insomnia ([@B28]). The main compounds of Semen Ziziphi spinosae include saponins, swertisin, and fatty oils ([@B29]). The oral administration of spinosin and swertisin prolongs the sleeping time *via* a serotonergic mechanism ([@B30]). Moreover, the pharmacological activities of Radix et Rhizoma Salviae miltiorrhizae exert anti-inflammatory and cardioprotective effects, rendering it preferable for the treatment of insomnia coupled with inflammation or cardiovascular diseases ([@B28]). Polygalae Radix, also a main component of BC, is primarily used for treating insomnia and depression ([@B31]). Recent pharmacological studies in animals have demonstrated that the constituents of Polygalae Radix can improve cognition and potentially exert antipsychotic, antioxidant, and anti-inflammatory effects ([@B31]). Taken together, BC might improve the total sleep time of PSI through multiple targets and mechanisms.

In consideration of the mild and slow synergistic effects of the various herbal components, which are not conducive to inducing sleep directly, low-dose ALP plays a complementary but vital role and effectively reduces the latency of sleep. Also, only fewer side effects are observed in the low-dose ALP.

Nevertheless, the present study has several limitations: 1) The size of the sample is small, and the variability of the individual result is high. 2) It is a retrospective study, lacking long-term follow-up data for some patients. Thus, further randomized controlled trials are essential to clarify the efficiency and mechanism of BC on PSI. 3) A comprehensive evaluation of the dose and treatment duration of BC is absent in this study, and thus, future randomized controlled trials are needed to address these issues. 4) Although the evidence of using ALP in PSI is insufficient, it is still widely used in clinics due to its cost-efficiency. In recent years, with the improving economy, the use of eszopiclone has been increasing gradually. Thus, choosing eszopiclone as control and combination drug would seem to be a viable alternative.
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